Abstract
Since 2008 there has been an onslaught of new drugs in the illicit marketplace. Often referred to as “research chemicals,” “designer drugs,” or “novel psychoactive substances” (NPS), these substances are used for their pharmacological effects which are often similar to more widely known drugs such as ecstasy or heroin. In some cases users specifically seek out these new chemicals, in other cases they are simply purchasing what they believe to be their normal drug of choice from a dealer, but the product is not what it is purported to be. Implementation of national and international systems to monitor the appearance of new compounds enables laboratories to be prepared with validated tests to detect them in biological specimens. The most common classes of NPS are synthetic cannabinoids, novel opioids, novel benzodiazepines, stimulants, and hallucinogens. Within these groups the compounds may be drugs that were originally synthesized for research purposes during the pursuit of new therapeutic agents such as the synthetic cannabinoid JWH-018 and the designer opioid U47700. Others like etizolam are compounds used in other countries but not commonly seen in the USA. Some are drugs synthesized specifically to circumvent legal controls. In all cases, these compounds present a unique challenge to forensic toxicology laboratories which must quickly develop and validate analytical methods for the identification and quantification in biological matrices.
This chapter is a condensed and updated version of an article originally published in Clinical and Forensic Toxicology News.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Kacinko SL, Papsun D (June 2016) Designer drugs keep evolving: novel psychoactive substances challenge laboratories and laws. Clinical and Forensic Toxicology News (Quarterly, AACC/CAP), 1-8. Available from: https://www.aacc.org/publications/clinical-and-forensic-toxicology-news
Cambridge University Press (1913) The second international opium conference. Am J Int Law 7:838–847
Hoffmann, A. (1996). LSD: Completely Personal. Presentation, 1996 Worlds of Consciousness Conference. Available at http://www.maps.org/news-letters/v06n3/06346hof.html.
EMCDDA–Europol (2009) Annual Report on the implementation of Council Decision 2005/387/JHA, European Monitoring Centre for Drugs and Drug Addiction and Europol, Publications Office of the European Union, Luxembourg
National Drug Early Warning System (NDEWS) https://www.drugabuse.gov/related-topics/trends-statistics/national-drug-early-warning-system-ndews
Gurney S (2014) Pharmacology, toxicology, and adverse effects of synthetic cannabinoid drugs. Forensic Sci Rev 26(1):53–78
Logan BK, Mohr ALA, Friscia M et al (2017) Reports of adverse events associated with use of novel psychoactive substances, 2013–2016: a review. J Anal Toxicol:1–38
Murphy TD, Weidenbach KN, Van Houten C (2013) Acute kidney injury associated with synthetic cannabinoid use—multiple states, 2012. MMWR Morb Mortal Wkly Rep 62:93–98
Drug Enforcement Agency, Office of Diversion Control, Drug & Chemical Identifcation Section. (2014). Phenazepam. Retrieved from http://www.deadiversion.usdoj.gov/drug_chem_info/phenazepam.pdf.
Araújo AM, Carvalho F, Bastos M de L et al (2015) The hallucinogenic world of tryptamines: an updated review. Arch Toxicol 89:1151–1173
Dean BV, Stellpflug SJ, Burnett AM et al (2013) 2C or not 2C: phenethylamine designer drug review. J Med Toxicol 9:172–178
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer Science+Business Media, LLC, part of Springer Nature
About this protocol
Cite this protocol
Kacinko, S.L., Papsun, D.M. (2019). The Evolving Landscape of Designer Drugs. In: Langman, L., Snozek, C. (eds) LC-MS in Drug Analysis. Methods in Molecular Biology, vol 1872. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4939-8823-5_13
Download citation
DOI: https://doi.org/10.1007/978-1-4939-8823-5_13
Published:
Publisher Name: Humana Press, New York, NY
Print ISBN: 978-1-4939-8822-8
Online ISBN: 978-1-4939-8823-5
eBook Packages: Springer Protocols